Amgen predicts a steady flow of biosimilar launches

Biosimilars/General | Posted 18/02/2022 post-comment0 Post your comment

Amgen CEO Robert Bradway predicted expanding the company’s biosimilars business with a steady flow of biosimilar launches at the J.P. Morgan Healthcare Conference, which was held on 11 January 2022.


Amgen already has five biosimilars approved in the US (of which four are launched) and three in Europe [1, 2] and expects revenues from these to bring in around US$2 billion for 2021. The company also expects to finally launch Amjevita (adalimumab-atto) in the US on 31 January 2023, after having to wait due to a settlement with AbbVie [3]. Amgevita (adalimumab) has been available in Europe since 2017 [2].

The company has more biosimilars in the pipeline and expects its 2030 biosimilars revenues to more than double the revenue from biosimilars in 2021. Amgen says it expects to be in first wave of biosimilars for Stelara (ustekinumab; ABP 654), Eylea (aflibercept) and Soliris (eculizumab). In addition, it says that it has three other biosimilars under development for a total biosimilars portfolio of 11.

In fact, Amgen says that its biosimilar candidates address around US$86 billions of originator biological sales in 2020. The company also does not expect biosimilar sales to impact on its sales of originator medicines. Mr Bradway said in his presentation that the efficiency of the biosimilars model is ‘not dilutive to margin’.

Related articles
Biosimilars of ustekinumab

Biosimilars of aflibercept

Biosimilars of eculizumab


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Biosimilares aprobados en Colombia

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Biosimilares aprobados en Colombia

iExplore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Boehringer Ingelheim finally signs licensing deal for Humira biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 18]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: Amgen

comment icon Comments (0)
Post your comment
Related content
CVS’ Cordavis to launch Sandoz’s Hyrimoz (adalimumab)
15 AA010699
Biosimilars/General Posted 03/10/2023
Proposal to widen access to trastuzumab in New Zealand
113 MD002138
Biosimilars/General Posted 28/07/2023
GADECCU position statement on biosimilars updated
136 AA011035
Biosimilars/General Posted 14/07/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010